Skip Nav Destination
1-2 of 2
Alan H. Bryce, MD, Rhett Ketterling, MD, Morie Gertz, MD, Steve Zeldenrust, MD, Martha Lacy, MD, Shaji Kumar, MD, Suzanne Hayman, MD, Francis Buadi, MD, Phillip Greipp, MD, John Lust, MD, Vincent Rajkumar, MD, Rafael Fonseca, MD, David Dingli, MD, Stephen Russell, MD, Robert Kyle, MD, Angela Dispenzieri, MD
Blood (2007) 110 (11): 2477.
Comparable Survival in Newly Diagnosed Multiple Myeloma (MM) after VAD Induction with High Dose Therapy Using Melphalan 140mg/M 2 + TBI 12 Gy (MEL+TBI) Versus Standard Therapy with VBMCP and No Benefit from Interferon (IFN) Maintenance: Final Clinical Results of Intergroup Trial S9321 in the Context of IFM 90 and MRC VII Trials.
Blood (2004) 104 (11): 539.